October 21, 2016 11:43 PM ET


Company Overview of Akebia Therapeutics, Inc.

Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is AKB-6899, a small molecule HIF-PH inhibitor to treat oncology and ophthalmology. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

245 First Street

Suite 1100

Cambridge, MA 02142

United States

Founded in 2007

63 Employees





Key Executives for Akebia Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 52
Total Annual Compensation: $757.5K
Chief Financial Officer, Senior Vice President and Treasurer
Age: 48
Total Annual Compensation: $467.7K
Chief Medical Officer and Senior Vice President
Age: 63
Total Annual Compensation: $573.3K
Compensation as of Fiscal Year 2015.

Akebia Therapeutics, Inc. Key Developments

Akebia Therapeutics, Inc. Announces Resignation of Anupam Dalal from the Board of Directors

Akebia Therapeutics, Inc. announced that Anupam Dalal, M.D. submitted an offer to resign from the Board of Directors of the company due to his change in job responsibility. On September 15, 2016, the Board accepted his offer to resign and Dr. Dalal resigned effective as of September 16, 2016.

Akebia Therapeutics, Inc. Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease

Akebia Therapeutics, Inc. announced the publication of positive results from a Phase 2b study of vadadustat, a once-daily oral HIF stabilizer, in development for the treatment of anemia related to chronic kidney disease (CKD). The study demonstrated that vadadustat increased and maintained hemoglobin levels in patients throughout the 20-week study in a predictable and controlled manner. The multicenter, randomized, double-blind, placebo-controlled study assessed the ability of oral, once-daily vadadustat to correct anemia in patients with stages 3a-5 non-dialysis dependent chronic kidney disease. Patients initiated treatment with either 450 mg of vadadustat or matching placebo, administered once daily for 20 weeks. The initial 450 mg daily dose of vadadustat was adjusted in accordance with the patient's hemoglobin (Hb) response using a dose titration algorithm designed to minimize Hb excursions above 13.0 g/dL. Patients were assigned to one of three study groups: recombinant erythropoietin stimulating agents (rESAs) treatment naïve, rESAs previously treated, or rESAs actively treated. Within each group, patients were randomized 2:1 to receive vadadustat or placebo and were stratified according to CKD stage and the presence or absence of diabetes mellitus. Findings from the study include: Vadadustat increased and maintained Hb levels in patients throughout the study when compared to placebo; by week two, mean Hb levels in the vadadustat group had increased significantly compared to placebo, plateaued by week six to week eight and were sustained throughout the 20 weeks of treatment, with limited Hb excursions and dose adjustments; Vadadustat improved iron mobilization compared to the placebo group, as measured by significant decreases in hepcidin and ferritin, as well as a significant increase in total iron binding capacity; and There was no difference between the vadadustat and placebo groups in the mean change from baseline in vascular endothelial growth factor (VEGF) levels at week 12 or end of treatment. Vadadustat was generally well tolerated in the Phase 2b trial and overall adverse events were balanced between the treatment and placebo groups.

Akebia Therapeutics, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-13-2016 11:45 AM

Akebia Therapeutics, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-13-2016 11:45 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: John P. Butler, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Akebia Therapeutics, Inc., please visit www.akebia.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.